Skip to main content
Caplight Logo









Kurve Therapeutics, Inc.

Kurve Therapeutics, Inc.

Private
Lynnwood, WashingtonHealthcare & Life Scienceshttps://kurvetx.com/

Last Round

Crowdfunding

Aug 9, 2022

Est. Valuation

$341.79M

Total Funding Raised

$50M

Company Overview

Kurve Therapeutics, Inc. is a medical technology and drug formulation company that develops treatments for neurodegenerative diseases. The company's core technology is its patented Controlled Particle Dispersion® (CPD), an intranasal drug delivery system designed to bypass the blood-brain barrier. This allows for more effective delivery of therapies for complex CNS disorders, including Alzheimer's disease, Parkinson's disease, and cognitive aging. The company's lead product is ViaNase®, a device that utilizes the CPD technology. Kurve Therapeutics acquired the assets of its predecessor, Kurve Technology, Inc. (founded in 2001), in March 2022 and is advancing the technology towards Phase III clinical trials. The company is focused on developing drug/device combination therapies that offer faster, more effective drug delivery to the central nervous system with the goal of reducing side effects and costs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

intranasal drug deliveryblood-brain barrier bypassBBB bypassdrug delivery platformnose-to-brain deliveryCNS drug deliveryneurodegenerative diseasesAlzheimer's diseasedrug delivery devicemedtechViaNasedrug formulationParkinson's diseaseelectronic atomizerclinical trialsTraumatic Brain InjuryTBI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kurve Therapeutics, Inc. Comparables

Compare Kurve Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Kurve Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rocket Science Health Corp.
83%
Zeteo Biomedical
79%
MetP Pharma AG
78%

Kurve Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingAug 9, 2022

Key People

Founding team and executive leadership

Marc Giroux

Chairman And CEO

Executive Team

Kurve Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kurve Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kurve Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersLynnwood, Washington
Employee Range2
Year Founded2001
Last FundingAug 9, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?